Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Grf(1-43)-oh
2. Growth Hormone Releasing Factor 43
3. Hpgrf(1-43)oh
4. Rat Growth Hormone-releasing Factor(1-43)
5. Rgrf 43
6. Rgrf(1-43)-oh
7. Rgrf(1-43)oh
8. Rhgrf(1-43)
9. Somaotropin Releasing Hormone (1-43)oh
10. Somatotropin Releasing Factor 43
1. 86472-71-1
2. Rgrf 43
3. Hpgrf(1-43)oh
4. Rhgrf(1-43)
5. Rgrf(1-43)-oh
6. Grf(1-43)-oh
7. Somatotropin Releasing Factor 43
8. Growth Hormone Releasing Factor 43
9. Somatropin Recombinant
10. Somaotropin Releasing Hormone (1-43)oh
11. Rat Growth Hormone-releasing Factor(1-43)
12. Dtxsid30235580
13. Somatoliberin (human Pancreatic Islet), 1-l-histidine-8-l-serine -12-l-arginine-13-l-isoleucine-18-l-tyrosine-24-l-histidine-25-l-glutamic Acid-28-l-asparagine-34-l-arginine-38-l-glutamine-39-l-arginine-40-l-serine-42-l-phenylalanine-43-l-asparagine-44-de-l-leucinamide-
Molecular Weight | 5234 g/mol |
---|---|
Molecular Formula | C225H360N76O67S |
XLogP3 | -23.5 |
Hydrogen Bond Donor Count | 86 |
Hydrogen Bond Acceptor Count | 79 |
Rotatable Bond Count | 189 |
Exact Mass | 5232.6886961 g/mol |
Monoisotopic Mass | 5230.6819865 g/mol |
Topological Polar Surface Area | 2440 Ų |
Heavy Atom Count | 369 |
Formal Charge | 0 |
Complexity | 13100 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 45 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : ENOMARK Group of Companies stands as a prominent Contract Manufacturer, boasting a cutting-edge manufacturing facility in Ahmadabad (Gujarat) that complies with WHO-GMP standards. ...
About the Company : Minglang chemical is owned by Minglang Group, is a large manufacturer of fine chemical and cosmetic materials that integrates R&D, production and sales together. It is located in t...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 498
2018 Revenue in Millions : 558
Growth (%) : -11
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2020 Revenue in Millions : 45
2019 Revenue in Millions : 51
Growth (%) : -12
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 427
2019 Revenue in Millions : 498
Growth (%) : -14
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2021 Revenue in Millions : 35
2020 Revenue in Millions : 44
Growth (%) : -12
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 389
2020 Revenue in Millions : 427
Growth (%) : -9
Main Therapeutic Indication : Rare Diseases
Currency : USD
2022 Revenue in Millions : 29
2021 Revenue in Millions : 35
Growth (%) : -17
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 20
2022 Revenue in Millions : 29
Growth (%) : -31
Main Therapeutic Indication : Rare Diseases
Currency : USD
2022 Revenue in Millions : 360
2021 Revenue in Millions : 389
Growth (%) : -7
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 539
2022 Revenue in Millions : 360
Growth (%) : 50
Main Therapeutic Indication : Harmonal Disorders
Currency : USD
2015 Revenue in Millions : 325
2014 Revenue in Millions : 312
Growth (%) : -4%
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?